A prospective analysis of breakthrough haemolysis in two Phase 3 randomised studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal haemoglobinuria

BRITISH JOURNAL OF HAEMATOLOGY(2019)

引用 0|浏览13
暂无评分
关键词
PNH
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要